Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.75 GBX | 0.00% | -6.52% | +9.14% |
Apr. 05 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
Apr. 05 | RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 | CI |
Sales 2024 * | 2.24M 2.8M | Sales 2025 * | 3.28M 4.09M | Capitalization | 6.67M 8.31M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.25M | Net income 2025 * | - 0 | EV / Sales 2024 * | 1.34 x |
Net cash position 2024 * | 3.66M 4.56M | Net cash position 2025 * | 2.95M 3.67M | EV / Sales 2025 * | 1.14 x |
P/E ratio 2024 * |
-2.48
x | P/E ratio 2025 * |
-7.17
x | Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.93% |
Latest transcript on RUA Life Sciences plc
1 week | -6.52% | ||
Current month | +19.44% | ||
1 month | +13.76% | ||
3 months | -12.24% | ||
6 months | -24.56% | ||
Current year | +9.14% |
Managers | Title | Age | Since |
---|---|---|---|
Lachlan Smith
DFI | Director of Finance/CFO | - | 21-11-30 |
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John McKenna
BRD | Director/Board Member | 71 | 16-10-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John Louis Ely
BRD | Director/Board Member | 73 | - |
Director/Board Member | 57 | 21-01-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 10.75 | 0.00% | 53,279 |
24-04-22 | 10.75 | -2.27% | 276,581 |
24-04-19 | 11 | -4.35% | 267,685 |
24-04-18 | 11.5 | 0.00% | 262,342 |
24-04-17 | 11.5 | 0.00% | 60,441 |
Delayed Quote London S.E., April 23, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.14% | 8.23M | |
+8.35% | 209B | |
+9.41% | 175B | |
+11.75% | 131B | |
+19.34% | 99.98B | |
-0.84% | 61.12B | |
+15.08% | 52.34B | |
-2.10% | 46.5B | |
+0.10% | 39.24B | |
+11.50% | 38.47B |
- Stock Market
- Equities
- AOR Stock